Precision Medicine & Genomics
Companies using AI to analyze genomic, proteomic, metabolomic, or multi-omics data to provide personalized treatment recommendations, identify genetic risks, or develop targeted therapies. Includes genomic sequencing platforms with AI analysis, preventive medicine based on genetic risk assessment, and longevity care based on molecular and genetic data.
Companies(5)
Deep Genomics
Deep Genomics is an AI therapeutics company that uses its BioFM Model Platform to discover novel targets and design life-changing genetic medicines for patients.
Element Biosciences
Element Biosciences develops innovative genetic analysis tools, empowering the scientific community with freedom and flexibility to accelerate biological discoveries.
Foundation Medicine
Foundation Medicine is a precision medicine company transforming cancer care by providing high-quality, transformative diagnostic solutions.
Galatea Bio
Galatea Bio is a genomics company developing AI-powered tools to analyze genetic data and identify disease risk factors for precision medicine.
Tempus
Tempus AI applies artificial intelligence to clinical and molecular data to advance precision medicine, helping physicians make data-driven decisions for personalized patient care.
Related Articles
All News →
What Healthcare AI Can Learn From Vertical AI in Construction
The health AI industry's most durable companies will be those that go deepest in a single clinical domain — not the ones that build the most general-purpose platform. The success of vertical AI in adjacent industries offers a clear template.
Tempus AI Reports 75% Revenue Growth in Q1 2026, Driven by Genomics and Data Licensing
Tempus AI has reported first-quarter 2026 revenue of $255 million, a 75% increase year-over-year, driven by strong growth in its genomics testing and data licensing segments as the company continues its post-IPO expansion.
Aidoc Raises $150 Million Series E Led by Goldman Sachs to Scale Clinical Foundation Model
Aidoc has closed a $150 million Series E round led by Goldman Sachs, with participation from existing investors, to scale its CARE clinical AI foundation model and expand its presence in radiology and emergency medicine workflows globally.